معرفی
Payel Chatterjee is an Associate Research Scientist in the Department of Cardiovascular Medicine at Yale University School of Medicine. She holds a PhD from Bowling Green State University (2018) in Microbiology/Infectious Disease, an MSc from Calcutta University (2010), and a BS (Honors) in Microbiology (2008). Her research focuses on vascular smooth muscle cell (VSMC) biology, epigenetic regulation in atherosclerosis, and chromatin remodeling mechanisms. Key collaborators include Dr. Kathleen Martin and Dr. Daniel Greif. Recent work introduces the concept of “Athero-Oncology,” exploring tumor-like behaviors in smooth muscle cells driving atherosclerosis progression. She investigates SUV39H1-mediated epigenetic pathways and ALK5/MTORC1 crosstalk as therapeutic targets. Chatterjee’s studies bridge molecular mechanisms with clinical implications in vascular diseases.
Educational Background:
- PhD, Microbiology/Infectious Disease, Bowling Green State University (2018)
- MSc, Microbiology, Calcutta University (2010)
- BS (Honors), Microbiology, Calcutta University (2008)
Research emphasizes chromatin dynamics in VSMC plasticity, with contributions to understanding how histone modifiers (e.g., p300, CBP, SUV39H1) regulate vascular pathology. Her work highlights translational potential for epigenetic therapies targeting atherosclerosis and vascular diseases. Publications in Circulation and Arteriosclerosis Thrombosis and Vascular Biology reflect this focus.
Collaborations span interdisciplinary teams at Yale, including the Martin Lab. Current projects explore ALK5/MTORC1 signaling interactions and rapamycin’s therapeutic efficacy in VSMC differentiation. While no formal student advisees are listed, her work positions her as a key contributor to cardiovascular research programs at Yale School of Medicine.
